tiprankstipranks
Trending News
More News >
Cyclopharm Limited (AU:CYC)
ASX:CYC
Australian Market

Cyclopharm Limited (CYC) AI Stock Analysis

Compare
13 Followers

Top Page

AU

Cyclopharm Limited

(Sydney:CYC)

Rating:44Neutral
Price Target:
AU$1.00
▼(-4.76%Downside)
Cyclopharm Limited's overall stock score is primarily influenced by its weak financial performance and unfavorable technical indicators. The company's persistent losses and negative cash flows significantly weigh down its score, while the technical analysis indicates a bearish market sentiment. The negative P/E ratio further complicates its valuation, making it a less attractive investment at this time.

Cyclopharm Limited (CYC) vs. iShares MSCI Australia ETF (EWA)

Cyclopharm Limited Business Overview & Revenue Model

Company DescriptionCyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
How the Company Makes MoneyCyclopharm Limited generates revenue through the sale and distribution of its Technegas products and associated consumables. The company's revenue model is centered around the recurring sales of Technegas generators and the consumables required for their operation, such as crucibles and patient administration sets. These consumables are essential for every patient scan, thus creating a steady stream of revenue. Additionally, Cyclopharm is expanding its market presence by obtaining regulatory approvals in new regions, which can lead to increased sales. The company also engages in strategic partnerships and collaborations with healthcare providers and distributors to enhance market penetration and drive growth.

Cyclopharm Limited Financial Statement Overview

Summary
Cyclopharm Limited is facing significant financial challenges with consistent losses and negative cash flows. The company's revenue growth is overshadowed by negative profitability metrics, such as EBIT and net income. Despite a strong equity position, the negative cash flow generation poses substantial risks to its financial health.
Income Statement
35
Negative
Cyclopharm Limited has shown consistent growth in revenue over the years, with a revenue growth rate of 1.6% from 2023 to 2024. However, the company is struggling with profitability, evidenced by persistent negative EBIT and net income, resulting in negative profit margins. Despite some growth in gross profit, the absence of positive net income and EBIT indicates significant challenges in operational efficiency and profitability.
Balance Sheet
45
Neutral
The balance sheet shows a relatively strong equity position with a Debt-to-Equity ratio of 0.19, indicating low leverage. The equity ratio stands at 68.8%, reflecting financial stability and a cushion against liabilities. However, the company has been consistently reporting net losses, impacting the return on equity negatively.
Cash Flow
30
Negative
Cyclopharm Limited's cash flow statement reveals ongoing challenges in generating positive cash flow, with a negative operating cash flow and free cash flow in 2024. The free cash flow growth rate and operating cash flow to net income ratio are concerning, indicating difficulties in sustaining operations through internal cash generation.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
27.57M27.14M23.22M17.70M14.68M
Gross Profit
17.93M4.50M5.94M3.20M2.08M
EBIT
-14.35M-9.22M-7.28M-6.43M-8.08M
EBITDA
-13.69M-3.03M-5.36M-4.19M-4.86M
Net Income Common Stockholders
-13.20M-4.70M-6.61M-5.04M-6.04M
Balance SheetCash, Cash Equivalents and Short-Term Investments
20.57M11.73M20.30M29.25M1.87M
Total Assets
62.13M45.91M49.54M55.74M28.28M
Total Debt
8.29M4.23M4.33M4.51M4.71M
Net Debt
-12.28M-7.50M-15.96M-24.74M2.83M
Total Liabilities
19.40M13.65M13.01M12.67M11.16M
Stockholders Equity
42.73M32.26M36.54M43.07M17.12M
Cash FlowFree Cash Flow
-13.55M-7.74M-8.21M-2.79M-9.47M
Operating Cash Flow
-12.57M-7.20M-6.66M-1.63M-8.93M
Investing Cash Flow
-971.86K-508.47K-1.55M-1.16M-874.19K
Financing Cash Flow
22.22M-1.02M-725.64K30.17M-985.96K

Cyclopharm Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.05
Price Trends
50DMA
1.18
Negative
100DMA
1.50
Negative
200DMA
1.52
Negative
Market Momentum
MACD
-0.03
Positive
RSI
37.16
Neutral
STOCH
6.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYC, the sentiment is Negative. The current price of 1.05 is below the 20-day moving average (MA) of 1.18, below the 50-day MA of 1.18, and below the 200-day MA of 1.52, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 37.16 is Neutral, neither overbought nor oversold. The STOCH value of 6.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CYC.

Cyclopharm Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
AUCYC
44
Neutral
AU$116.69M-35.20%4.68%-155.42%
$11.41B46.6220.61%1.61%
$76.11B26.6715.38%1.85%
$848.17M72.509.23%
AURHT
61
Neutral
AU$18.38M140.00-3.11%89.13%69.57%
AUPYC
53
Neutral
AU$699.91M-112.97%-84.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CYC
Cyclopharm Limited
1.05
-0.53
-33.54%
CHEOF
Cochlear
174.05
-41.96
-19.43%
CMXHF
CSL
151.50
-33.15
-17.95%
NNCSF
Nanosonics Limited
2.61
0.62
31.16%
AU:PYC
PYC Therapeutics Limited
1.20
0.16
15.38%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%

Cyclopharm Limited Corporate Events

Cyclopharm Limited Secures Shareholder Approval for Key Resolutions at AGM
May 30, 2025

Cyclopharm Limited announced that all resolutions proposed at its Annual General Meeting on May 30, 2025, were successfully passed. This includes approvals related to remuneration reports, director re-elections, and performance rights grants, which reflect strong shareholder support and may positively impact the company’s governance and operational strategies.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Limited Releases Cautious Financial Projections
May 30, 2025

Cyclopharm Limited has released a presentation containing forward-looking statements and projections about its future financial performance and market conditions. The company emphasizes that these projections are based on assumptions and are subject to uncertainties, and it does not guarantee their accuracy. The release highlights the company’s cautious approach to future predictions and its focus on managing stakeholder expectations.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Achieves Record Sales with US Expansion in 2024
May 30, 2025

Cyclopharm Limited reported a record year in 2024, marked by the commencement of commercial sales in the United States following FDA approval. The company’s revenue reached $27.6 million, with Technegas sales contributing significantly. Despite a loss after tax of $13.2 million, Cyclopharm’s strategic expansion into the US market and its growing third-party distribution business are set to drive future growth. The company’s focus on expanding the use of Technegas for conditions beyond pulmonary embolism, such as COPD and asthma, indicates potential for accessing larger markets and achieving long-term growth.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Limited Expands US Market Presence with Technegas™
May 30, 2025

Cyclopharm Limited has entered a new growth phase following the USFDA approval of Technegas™ for lung imaging, which has significantly boosted its sales in the United States. The company achieved a 131% increase in US sales in 2024, with continued momentum into 2025, and has secured key agreements with major healthcare providers, enhancing its market reach. The expansion into the US market is expected to accelerate research into new clinical applications, potentially unlocking a global market opportunity estimated at US$900 million. Additionally, Cyclopharm is strengthening its third-party distribution business, contributing to its revenue diversity and margin resilience.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Limited Announces 2025 Annual General Meeting
Apr 29, 2025

Cyclopharm Limited has announced its Annual General Meeting, scheduled for May 30, 2025, in Kingsgrove, NSW. The meeting will address several key resolutions, including financial statements, director re-election, and approval of performance rights and remuneration. This meeting is crucial for stakeholders as it will determine strategic decisions impacting the company’s governance and financial strategies.

Cyclopharm Expands US Presence with Technegas® Installation at Major Military Hospital
Apr 10, 2025

Cyclopharm Limited announced the installation of its Technegas® technology at Brooke Army Medical Center (BAMC) in Houston, Texas, marking the first Department of Defense hospital to adopt this system. This installation is part of a 5-year contract with the US Federal Government, positioning Cyclopharm as a significant player in the US market. The deployment at BAMC, the largest military medical facility in the US, is a strategic move to expand Technegas® usage across other Veteran Administration and DoD hospitals, enhancing Cyclopharm’s market presence and growth opportunities.

Cyclopharm Limited Revises AGM Date and Director Nomination Deadline
Apr 9, 2025

Cyclopharm Limited has announced a revised date for its Annual General Meeting, now scheduled for May 30, 2025, with the election of directors as a key agenda item. The new deadline for director nominations is set for April 9, 2025. This announcement, approved by CEO James McBrayer, is significant for stakeholders as it outlines the company’s governance timeline and potential leadership changes.

Cyclopharm Limited Releases 2024 Corporate Governance Statement
Mar 27, 2025

Cyclopharm Limited has released its corporate governance statement for the financial year ending December 31, 2024, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles, highlighting their commitment to transparency and accountability in management and oversight. This announcement reinforces Cyclopharm’s dedication to maintaining high governance standards, potentially strengthening its position in the market and assuring stakeholders of its robust governance practices.

Cyclopharm Limited’s 2024 Annual Report Highlights Global Leadership in Lung Imaging
Mar 27, 2025

Cyclopharm Limited has released its 2024 Annual Report, highlighting its position as a global leader in functional lung ventilation imaging. The report underscores the company’s commitment to innovation and its strong market presence with Technegas™, which is widely used in 66 countries, reflecting its significant impact on the healthcare industry.

Cyclopharm to Present at NWR Virtual Healthcare Conference
Mar 19, 2025

Cyclopharm Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO James McBrayer will present. This engagement highlights Cyclopharm’s ongoing efforts to engage with stakeholders and showcase its advancements in nuclear medicine, potentially enhancing its industry positioning and stakeholder relations.

Cyclopharm to Provide Key Business Update on March 19, 2025
Mar 17, 2025

Cyclopharm Limited announced a business update scheduled for March 19, 2025, which will cover the company’s FY 2024 results, a new five-year contract with the USA Veterans Administration, and progress in USA commercialization. This update signifies Cyclopharm’s strategic advancements in the U.S. market, potentially enhancing its industry positioning and stakeholder value.

Cyclopharm Secures 5-Year Agreement with US Veterans Administration
Mar 13, 2025

Cyclopharm Limited has secured a five-year Federal Supply Schedule agreement with the US Veterans Health Administration, marking a significant expansion of its Technegas product within the US federal healthcare system. This agreement simplifies procurement processes and ensures a consistent supply of Technegas, strengthening Cyclopharm’s position in the US market despite uncertainties in healthcare funding policies.

Cyclopharm Limited Announces AGM Date and Director Nomination Deadline
Mar 10, 2025

Cyclopharm Limited has announced that its Annual General Meeting will be held on May 13, 2025, with director nominations closing on March 24, 2025. This announcement is part of the company’s ongoing governance and operational updates, which could impact its strategic direction and stakeholder engagement.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.